Week by week
Amgens statement added that the long half-life, combined with its dual mechanism of action, means the drug may allow for greater durability or reduce the likelihood of weight regain after treatment stops
Some patients may ask about switching from semaglutide to tirzepatide if weight loss slows, side effects become difficult, blood sugar goals change, or they are not seeing the desired response
Published online January 2, 2026:10600280251407145
After 72 weeks: Participants taking 6 mg of orforglipron lost an average of 7.5% of their body weight (equivalent to 9 mg of Foundayo) Participants taking 12 mg or 37 mg of orforglipron lost an average of 8.4% and 11.2%, respectively (equivalent to 14.5 mg or 17.2 mg of Foundayo, respectively) Side effects and risks of GLP-1s The most common side effects from these medicines are mild gastrointestinal (GI) issues, such as: Vomiting Diarrhea Abdominal pain Rare but serious side effects of GLP-1s may include: Pancreatitis, or inflammation of the pancreas Gallbladder disease (including gallstones or gallbladder inflammation) Low blood sugar ( hypoglycemia ), particularly in people who also take insulin or certain pills for diabetes Severe allergic reactions Severe gastrointestinal reactions, which may lead to dehydration and related kidney problems Diabetic retinopathy complications in people with this eye disease Risk of pulmonary aspiration ( stomach contents entering the lungs) during surgery in people undergoing deep sedation or anesthesia GLP-1s also carry a boxed warning because they caused thyroid C-cell tumors in studies of rats
Phase 2 clinical trials involved 338 adults with obesity (BMI 30 or more) and overweight (BMI of 2729.99) with one or more weight-related conditions such as high blood pressure, high cholesterol levels, heart disease, and type 2 diabetes
